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Targeted Molecular Imaging
olecular imaging is a technique that uses molecules or generates signals
from molecules to image the structure and function of molecular systems
(1). The procedure may involve proteins, cellular subassemblies, cells, or-
gan systems, or the whole organism, but in each case the image obtained displays spe-
cific molecular components of structures or molecular functions.
Molecular medicine represents the merger of modern biology and medicine.
Diseases result from internally and externally derived molecular errors that instruct
cells to transform into the phenotypes of disease; the genome coded by four nu-
cleotides to yield instructions is translated into another code assembly by combinations
of 20 amino acids to form proteins upon which the structure and function of cells are
then based.
Advances in molecular medicine are associated with one wave of technology after
another, and range from various biotechnologies to more recent nanotechnologies
which are examining how biological systems assemble molecular motors and levers, as
well as communicate, compute, and store information. Positron emission tomography
(PET) and microPET use positron-labeled molecules to image processes such as metab-
olism, cell communication, and gene expression. Single photon emission computed to-
mography (SPECT) and microSPECT systems are used with PET to attain common
goals, but employ molecules labeled with single-photon emitters. Optical imaging sys-
tems use fluorescence or bioluminescence to image gene expression in cells through
the use of reporter genes that yield a protein which emits.
Structural imaging systems have been fused with molecular imaging technologies,
and such mergers include PET/ computed tomography (CT), SPECT/CT, optical fluo-
rescence imaging (used to obtain anatomical photographs), magnetic resonance imag-
ing (MRI), functional MRI, and magnetic resonance spectroscopy using molecular
imaging probes. Nuclear imaging benefits greatly from molecular probes originating
from biochemistry and pharmaceuticals with relatively poor spatial resolution. Other
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Molecular imaging aims to visualize the cellular and molecular processes
occurring in living tissues, and for the imaging  of specific molecules in vivo, the
development of reporter probes and dedicated imaging equipment is most impor-
tant. Reporter genes can be used to monitor the delivery and magnitude of thera-
peutic gene transfer, and the time variation involved. Imaging technologies such
as micro-PET, SPECT, MRI and CT, as well as optical imaging systems, are able
to non-invasively detect, measure, and report the simultaneous expression of
multiple meaningful genes. It is believed that recent advances in reporter probes,
imaging technologies and gene transfer strategies will enhance the effectiveness
of gene therapy trials. imaging approaches suffer from nonspecificity (CT), low
signal penetration through tissue (optical), or the low signal
strength from specific molecular constituents (MRI).
This paper briefly reviews the nature of genes, gene ther-
apy and imaging, as well as the imaging of angiogenesis
and apoptosis.
DNA, Genes and Gene Therapy
The genetic information needed to sustain life is con-
tained in the DNA molecule, which is composed of four
chemical bases: adenine, thymine, cytosine and guanine.
Strands of these bases pair with each other to form a chro-
mosome around histone proteins. The nucleus of a human
cell contains 23 chromosome pairs, and is referred to as the
human genome, which contains approximately 60,000
100,000 genes; a single gene is a stretch of DNA and con-
sists of several thousand base pairs. A new molecule, RNA,
is synthesized by using DNA as a template when a gene
becomes active; the RNA acts as a template for the pro-
tein. Approximately 80,000 proteins perform all life-relat-
ed functions the inside and outside cells; to identify a func-
tion, a knowledge of the sequence of the human genome is
required. In order to identify new targets for the earlier de-
tection of diseases, to evaluate molecular markers for ther-
apeutic responses, and use imaging for drug selection and
gene expression, the human genome project will determine
the exact sequence of 3 billion base pairs in human DNA.
If a particular gene has mutated, it may not be able to
produce protein or it may function poorly or too aggres-
sively. This disrupts cell and tissue functions and causes ab-
normal cell behavior, leading to symptoms of diseases.
Gene therapy involves the deliberate transfer of DNA for
the correction of mutated genes through the introduction
of a normal gene into the cell or by direct repair (3).
Viruses are ideal vectors, being naturally suited to the de-
livery of genetic material into target cells. RNA viruses,
such as retroviruses, reverse the normal sequence of events
by converting their RNA genome back into DNA by using
reverse transcriptase, and the DNA thus produced is inte-
grated into the genome. A DNA coding sequence is de-
rived from cellular messenger RNA, paving the way for
gene cloning (4). Reverse transcriptase synthesizes a sec-
ond complementary DNA (cDNA) strand, a process which
yields a double-stranded DNA molecule.
Polymerase chain reaction is the method used fo produce
amplifying cloned DNA in sufficient quantities. After
cloning in the expression vector, transfection into bacteria
allows the large-scale manufacture of milligram-to-gram
quantities of the cDNA-vector complex. The cloned cDNA
must be purified from the bacteria, after which it is suitable
for transfer into the gene delivery vehicle. Genes in the
form of DNA are delivered to a target cell by packing
them in a virus, applying them in the form of plasmid or
plasmid in a synthetic delivery system, or delivering them
through direct injection, electroporation, gene guns, or ra-
diofrequency pulses. Once inside the cells, transgenes can
be found within the cytoplasm or in the nucleus, or may be
integrated into the host genome. The duration and level of
foreign gene expression is usually long after the gene is in-
corporated into the nucleus (5).
Current gene technology has focused on the use of viral
vectors which can provide highly efficient transduction and
high levels of gene expression (6). Adenoviruses contain
double-stranded DNA and enter the cell by receptor-medi-
ated endocytosis. They are quite immunogenic and do not
integrate into the host genome (5). Retroviruses contain a
single-stranded RNA genome, and enter the cell by direct
fusion with the plasma membrane prior to integration into
the host chromosome during cell division. They infect only
dividing cells however, and become inactivated by serum
complement. Herpes simplex virus-derived amplicons have
been used as an alternative method of gene delivery.
Amplicons are plasmids that can be packaged into recom-
binant viral particles and used to transfer anticancer genes
with little toxicity; these particles are often unstable, im-
munogenic, and can have lower titers, and oncogene acti-
vation may occur, leading to the development of cancer.
Transfection methods using nonviral artificial vectors car-
rying plasmid DNA have therefore been developed; vec-
tors include cationic liposomes, poly-L-lysine-DNA com-
plexes, DNA-coated microprojectiles, dendrimers, and
free-plasmid DNA. Although these nonviral vector systems
seem to work to some degree ex vivo, gene transfer is gen-
erally lower in vivo (7).
In the setting of genetic deficiencies, the goal of therapy
is the restoration of deficient or absent expression of a crit-
ical gene product. This has been applied to cystic fibrosis
(transmembrane conductance regulator), adenosine deami-
nase deficiency and Gaucher’s disease (beta-glucocerebro-
side deficiency) (8). Chronic pathologic processes such as
peripheral vascular disease may be amenable to gene ther-
apy and many gene therapy protocols to date have concen-
trated on treatments for cancer (9). In general, cancers in-
volve one mutation to a protooncogene (yielding onco-
gene) and at least one to a tumor suppressor gene, allowing
the cancer to proliferate. Gene therapy pursues a variety
of strategies, namely oncogene inactivation, tumor sup-
pressor gene replacement, immunopotentiation, molecular
chemotherapy, and drug resistance genes. Emphasis will be
on genetically modifying cells of the body’s own immune
system to fight tumors (10). Oncogene activity can be in-
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alytic RNA molecules or antioncoprotein antibodies.
Cellular proliferation involves an intricate balance be-
tween signals driving cell-cycle progression, those main-
taining quiescence, and those initiating the pathway for cel-
lular destruction (i.e., apoptosis). Antibodies directed
against fas ligand expressed on the tumor cell may mimic
fas/fas ligand interactions and trigger the apoptotic death
of the tumor (11). Tumor suppressor gene, p53, plays in
regulating tumor cell apoptosis. Retroviral p53 gene com-
plexes injected into refractory p53-deficient lung carcino-
ma showed tumor regression (12). Expression of p53 is
synergistic with cisplatin, and adjacent tumor cells that
have not been transduced are also killed by the bystander
effect (13). Other tumor suppressor genes include BRCA1,
retinoblastoma, and Wilm’s tumor genes (14). Passive im-
munotherapy involves harvesting tumor-infiltrating lym-
phocytes and treating them to express increased cytokines.
Various cytokines including IL-2, IL-4, IL-12, GM-CSF tu-
mor necrosis factor and interferon, have been inserted into
tumors and have increased anti-tumor immunity (15, 16).
Active immunotherapy genetically modifies tumor cells, to
increase the expression of antigen-presenting molecules or
local concentrations of cytokines; cells are irradiated prior
to being returned to the patient. This approach, cancer vac-
cination, has been the subject of clinical trials for metastatic
melanoma (17).
Tumor-lymphocyte interaction is facilitated by co-stimu-
latory ligand-receptor (B7-CD28) interaction. B7 is absent
in many tumors, and re-establishing its expression has been
shown to facilitate immune recognition (18). An alterna-
tive approach to increasing tumor immunogenicity is to ex-
press foreign HLA antigens in the tumor by direct intratu-
moral transfer which causes the tumor to be rejected by
the host immune system (19). Molecular chemotherapy
and drug-resistant genes direct chemotherapeutic drug pro-
duction by the tumor itself. A suicide gene, herpes simplex
virus-1 thymidine kinase (HSV1-tk), that encodes a pro-
drug-converting enzyme, thymidine kinase, is inserted into
tumor cells, and a specific nontoxic prodrug (ganciclovir) is
then administered systematically (20). The prodrug is con-
verted into a toxic antimetabolite which causes tumor cell
death. The cytosine deaminase gene expressed by tumor
cells allows 5-fluorocytosine (5-FC) to be converted into 5-
fluorouracil (5-FU), an antimetabolite; significant anti-tu-
mor activity was reported when a cytosine deaminase-
based gene transfer system was used in colorectal cancer
(21).
Irrespective of the specific type of delivery vehicle used,
the gene must be delivered efficiently to its intended tar-
get. Although vectors have been injected systemically, this
has proven less efficacious than local delivery. Emboliza-
tion techniques may aid in prolonging vector contact with
the target cells by delaying washout and thereby further
enhancing target cell uptake (22). Other delivery strategies
include image-guided delivery to target tissues or the tu-
mor through stereotactically placed needles, and cavitary
administration using US, CT or MR guidance. Additional
interventional strategies have been employed to improve
gene delivery, including electroporation, microinjection,
particle bombardment, gene gun therapy, and high-fre-
quency ultrasound.
Approaches to Gene Imaging
Essential to the sampling of molecular information is the
use of highly specific imaging probes, sensitive systems
producing high resolution images, and appropriate amplifi-
cation (1). Considerable research efforts are being devoted
to the development of suitable in vivo affinity ligands
(molecular probes), efficient organ and intracellular target-
ing, optimal amplification and imaging systems which pro-
vide both high resolution and high sensitivity. Current
therapeutic drugs are directed against approximately 500
molecular targets (receptors in 45% of these, enzymes in
30%, and others in 25%). In-vivo imaging methods (Table
1) are being developed for gene delivery by using novel
formulations of DNA, and for gene expression by using
cell-specific, replication-activated, drug-controlled expres-
sion systems. Nuclear and optical imaging techniques are
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6 times more sensitive than MRI or CT for probe
detection, but both lack significant spatial resolution. High-
resolution 3-D MRI or CT maps of transgene expression
can be generated, and a variety of targeted MR or CT con-
trast agents have been developed for molecular imaging
(23). However, if less abundant targets are to be probed
for, MRI or CT will require amplification strategies which
provide more sensitive detection. In target overexpression,
hyperexpression of a targeted molecule results in the static
accumulation of contrast agent at the target site. If the tar-
geted gene product is internalized the probed gene product
can participate multiple times to sequester targeted con-
trast agent within the cells. The endogenous reporters ex-
ploit the inherent MRI ability of the gene product to en-
hance MR signal within cells. Tyrosinase expression in-
creased a melanin production, and melanin has a high met-
al (iron) binding capacity, resulting in high MR signal inten-
sity. A contrast probe can be activated by a cellular protein
which can be imaged by utilizing antibodies or ligands to
target MR or CT contrast agents to cells. The expression of
wild-type transferrin receptor (TfR) correlates with cellular
proliferation, and the increased TfR levels found in cancer
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which is essential for cellular metabolism. The applicability
of TfR targeted MRI is underway to aid in earlier detection
of cancers. MRI techniques have also shown encouraging
results using substrate (EgadMe), which can be enzymati-
cally processed by  -galactosidase and can generate MRI
signals. Gliosarcoma cells with transfected human transfer-
rin receptor were imaged using iron oxide nanoparticles
conjugated with human holotransferrin. Direct imaging of
the expression of therapeutic genes requires the develop-
ment of many different radiolabeled probes, and thus the
development of a more general approach to the indirect
monitoring of therapeutic gene expression is needed.
Reporter gene imaging is one such potential approach and
has been used to study promoter/regulatory elements, in-
ducible promoters, and endogenous gene expression.
Reporter gene imaging involves the indirect visualization
of transcriptional and post-transcriptional regulation of tar-
get gene expression, and of specific intracellular protein-
protein interactions. Regulatory regions of genes (i.e., pro-
moters/enhancers) can be cloned and used to drive tran-
scription of reporter gene. One can indirectly monitor the
gene expression by introducing reporter gene with a pro-
moter into the target. Conventional methods to monitor
gene expression take advantage of reporter genes including
-galactosidase (24). Other methods make use of optical re-
porter genes, including luciferase or green fluorescent pro-
tein (GFP) (25). MRI offering higher spatial resolution (mi-
crometer) is more useful than nuclear technique for imag-
ing transgenic animals and cell trafficking, but less sensitive
(millimolar rather than picomolar). Near-infrared fluores-
cence imaging relies on light of a defined band-width as a
source of photons that encounter a fluorescent molecule
(optical contrast agent) which emits a signal that can be
captured with a high sensitivity charge-coupled-device
camera. One of the advantages of near-infrared optical
imaging is that quenched fluorescent after interaction with
their target can be used. It would be suitable to image en-
zymes, DNA and/or RNA targets. Multiple probes with
spectral characteristics can be used for multi- channel imag-
ing. Bioluminescent imaging exploits the emission of visi-
ble photons at a specific wave length arising from energy-
dependent reactions catalyzed by luciferases. Expression of
the bioluminescent reporter luciferase has been used to im-
age transformed tumor cells and bacterial organisms (1).
Two approaches are possible to adapt the reporter gene
concept for PET or SPECT. The reporter gene can be intro-
duced in such a way that it encodes for an enzyme that is
capable of trapping a specific tracer through the action of
that enzyme. A second approach uses a reporter gene that
encodes for an intracellular and/or extracellular receptor
capable of binding a tracer. The reporter gene introduced,
driven by a promoter of choice, is referred to as a trans-
gene. For all vectors, the common feature is a cDNA ex-
pression cassette containing the reporter gene of interest.
The promoter can be constitutive, inducible, and also cell-
specific. Wild-type HSV1-tk or a mutant HSV1-tk gene,
HSV1-sr39tk, are the reporter genes most commonly used
in current molecular imaging studies using radiolabeled
probes and PET imaging (26).
The use of cytosine cytosine deaminase as a reporter
gene, with 5-FC as a reporter probe, has been investigated
(27). The cytosine deaminase enzyme converts antifungal
agent 5-FC to highly toxic 5-FU which can block DNA and
protein synthesis through the substitution of uracil by 5-FU
in RNA and the inhibition of thymidilate synthetase by 5-
fluorodeoxyuridine monophosphate, resulting in impaired
DNA biosynthesis. Another reporter gene system uses the
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Table 1. Imaging of Gene Expression
Marker Protein Substrate or Ligand Method Mechanism
Cell surface
Somatostatin receptor Peptides Nuclear Affinity binding
Transferrin receptor Transferrin MRI Internalization
Fusion proteins Oxotechnetate Nuclear Transchelation
Intracellular
Thymidine kinase FIAU, ganciclovir Nuclear Phosphorylation
Cytosine deaminase Cytosine Nuclear Deamination
Tyrosinase Tyrosine, DOPA Nuclear, MRI Oxidation
Green fluorescent protein None Optical Fluorescence
Luciferase Luciferin Optical Bioluminescence
Cathepsin Fluorochromes Optical Fluorescence
-galactosidase Galactosylated chelators MRI Cleavage of galactose
Sodium iodide symporter Iodine Nuclear Trapping and organification
Note. FIAU = 2’-fluoro-2’-deoxy-1- -D-arabinofuranosyl-5-iodo-uracil, DOPA = dioxyphenyl-alaninedopamine type 2 receptor (D2R), which binds spiperone, a
D2R antagonist. The presence of F-18 fluorethyl spiperone
(FESP) results in probe accumulation in D2R-expressing
cells or tissue (28). The expression of HSV1-sr-39 tk and
D2R receptor genes can be imaged simultaneously with mi-
cro PET by using F-18 fluoropenciclovir and F-18 FESP
(29).
Somatostatin receptor subtype II (SSTR2) is another re-
porter gene, and through  the use of In-111, I-123 or Tc-
99m-labeled octreotide, SSTR2-positive neuroendocrine
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Fig. 1. Selected axial (top), coronal (middle) and sagittal (bottom) CT (left), SPECT (middle) and SPECT/CT (right) images of the ab-
domen demonstrate focal increased In-111 octreotide receptor uptake (24 hr after injection) in the pancreatic head, with islet cell tumor
expressing somatostatin receptor 2 or 5.and lung tumors can be demonstrated (30) (Fig. 1).
Somatostatin receptors such as D2R are members of the G-
protein-coupled receptor family, the largest family of cell-
surface receptors involved in signal transduction.
Somatostatin and related analogues produce an inhibitory
signal which is antiproliferative in cancer cells. The in-
hibitory effect of SSTR2 on cancer cell proliferation and
metastasis is the proposed application as a genetic reporter.
Tc-99m P829 (NeoTect) has been used to image lung tu-
mors with SSTR2, 3 or 5, and reporter cassettes inserted in
recombinant adenoviral vectors have included SSTR2
alone or in combination with thymidine kinase, cytosine
deaminase or GFP. The SSTR2 and TK genes were trans-
ferred by mean of the same Ad vector, and both gene
Kim
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Fig. 2. Selected axial (top), coronal (middle) and sagittal (bottom) CT (left), SPECT (middle) and SPECT/CT (right) images of the chest
reveal focal increased uptake of I-131 sodium iodide (24 hr after oral ingestion) by the metastatic follicular carcinoma present at the base
of the left lung.products were simultaneously detected due to internally
trapped Tc-99m P2045 and I-131 2’-fluoro-2’-deoxy-1- -
D-arabinofuranosyl-5-iodo-uracil (FIAU) using a gamma
camera which can image multiple radionuclides (31).
Octreotide probes conjugated with fluorescent labels can
detect somatostatin receptors through light-based imaging
(32). An adenoviral vector encoding both SSTR2 and en-
hanced GFP genes (Ad-SSTR2-GFP) has been developed;
the tumor xenograft was visualized after the uptake of Tc-
99m somatostatin peptide (P2045), using a gamma camera,
and also by fluorescent stereomicroscopic imaging (31).
Thyroid iodide uptake is basic to the clinical applications
of radioiodine (Fig. 2). Iodine uptake occurs across the
membrane of thyroid follicular cells through an active
transporter process mediated by N15, a sodium iodide
symporter (NIS). The NIS gene is localized on chromo-
some 9p12 13.2 and encodes a glycoprotein of 643 amino
acids. NIS is an integral protein of basolateral membrane
of thyroid follicular cells. NIS also transports technetium
pertechnetate and rhenium perrhenate in addition to io-
dide. Thyroid stimulating hormone (TSH) increases iodine
uptake, and NIS protein expression is upregulated by TSH.
The recent cloning of the NIS gene has improved the better
characterization of the molecular mechanisms underlying
iodide transport. In papillary and follicular thyroid carcino-
mas, NIS immunostaining has been positive in only a few
tumor cells, and no NIS protein expression has been de-
tected in anaplastic carcinomas. In thyroid carcinomas, de-
creased NIS levels account for the reduced iodide uptake
observed, and by targeting NIS expression in cancer cells
which concentrate iodide from plasma, radioiodine therapy
can thus be offered. It has been shown that gene transfer of
NIS into a variety of cell types confers increased radioio-
dine uptake by up to several hundredfold that of controls
in nonthyroid cancers as well as in thyroid cancer (33). The
NIS gene can be transfected to specific cancer cells, and the
effect of therapeutic anticancer regimens can be easilly
monitored by a gamma camera using radioiodine or tech-
netium pertechnetate. In breast carcinoma, 87% of 23 in-
vasive carcinomas and 83% of 6 ductal carcinomas in situ
expressed NIS, compared with 23% of 13 noncancerous
tissues adjacent to tumors and none of eight normal breast
tissue samples (34). This suggests that during malignant
transformation in human breast cancer, NIS is upregulated.
Imaging of Angiogenesis and Apoptosis
Angiogenesis involves the growth and remodeling of a
primitive vascular network into a complex one, and occurs
during embryonic development, the female reproductive
cycle, wound healing, and hair growth. The vascular net-
work in adults is regulated by angiogenic inducers and in-
hibitors, the balance of which shifts under pathologic condi-
tions, such as cancer and cardiovascular and immunologic
diseases, during which capillary growth is chaotic. Agonist
stimulators include vascular endothelial growth factor, ba-
sic fibroblast growth factor, angiopoietins, matrix metallo-
protease, integrin and cadherin. Endogenous inhibitors in-
clude thrombospondin, endostatin, angiostatin, troponin,
metallospondin and interleukins. Functional MRI and nu-
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Fig. 3. Planar whole body images of rats
bearing breast tumor (T) show an up-
take of Tc-99m ethylene dicystein (EC)-
endostatin. Note less uptakes after en-
dostatin (right) and paclitaxel (PTXL)
treatments.
Effect of Endostatin and Paclitaxel treatment (day 7) on 
99mTc-EC-Endostatin uptake in mammary-tumor-bearing rats
1 Hour
PTXL Control End.clear techniques generate physiologic parameters such as
flow, perfusion, permeability, vascular structure and/or
volume fraction based on first-pass or equilibrium contrast
enhancement (35). A more specific imaging is to target spe-
cific target probes to markers expressed on altered neoen-
dothelial surface of tumor vessels. The phenotypic changes
occuring during therapy may not become apparent for
weeks or months. Examples include the targeting of en-
dothelial integrin  V 3, using paramagnetic liposomes for
MRI, and the targeting of angiogenesis-associated fi-
bronectin using optical probes, radiolabeled peptides ad-
hering to the glycoprotein IIb/IIIa receptor on the surface
of activated platelets, and also antibodies against tumor
growth factor  receptor (1). Tc-99m ethylene dicysteine
(EC)-endostatin has been tested in tumor-bearing rats as
well as in cancer patients (36) (Fig. 3).
Apoptosis, the process of programmed cell death critical
for organ development, tissue homeostasis, and the re-
moval of defective cells without causing concomitant in-
flammatory response. It depends on the multiple extracel-
lular signals, integration and amplification of signals, and
activation of effector proteases called caspases. Apoptosis
can be decreased in cancer, autoimmune disease and viral
infection, or increased in AIDS, ischemia, stroke and neu-
rodegenerative disorders. There are three pathways of
apoptosis (37). The first one involves signaling of a death
receptor (eg, Fas or tumor necrosis factor) which then acti-
vates caspases. The second one is initiated by the with-
drawal of growth factor which leads to the release of cy-
tochrome C from mitochondria followed by caspase activa-
tion, a process controlled by the Bcl-2 protein family. Third
one is induced by DNA damage that triggers the p53 path-
way of caspase activation. Caspase-mediated proteolysis
involving cellular changes such as cell shrinkage, mem-
brane blebbing, chromatin condensation and nuclear frag-
mentation, is irreversible. Caspase inhibitors may be useful
for ischemia, rejection or autoimmune diseases; caspase ac-
tivator, p53, may help induce efficient killing. During the
terminal stages of apoptosis, intracellular phosphatidylser-
ine (PS) is expressed on the cell surface and in annexin
contained in tumor cells; annexin V binds to cells with ab-
normally expressed PS. Tc-99m HYNIC or EC-annexin V
has been used to image the apoptosis occurring in cancer
and in transplant rejection (38) (Fig. 4).
Imaging of Drug and Radionuclide Gene Therapy
The in-vivo testing of drug effectiveness has led to major
bottlenecks. Molecular imaging however, can help to de-
termine the pharmacokinetics and pharmacodynamics of
Kim
208 Korean J Radiol 4(4), December 2003
Fig. 4. Planar whole-body images of a
breast tumor (arrows) in a rat demon-
strate 99mTc-EC-Annexin V uptake af-
ter paclitaxel treatment.
99mTc-EC-Annexin V (100 Ci/rat, iv) Uptake 3Days 
after Paclitaxel Treatment
5 min 1 hour
2 hours 4 hoursnewly developed drugs, and can also facilitate the develop-
ment of early and objective markers before phenotypic
changes become obvious. It is, in addition, useful for prob-
ing for a specific molecular target enzyme, receptor or sig-
nal transduction pathway against which a therapeutic drug
is directed. Imaging is the objective method to assess long-
term and often expensive drug testing. It is also helpful to
understand delivery barriers for new therapeutic agents.
In addition to the application of somatostatin analogues
for imaging, the same and related analogues can be conju-
gated with therapeutic radionuclides (Y-90, I-131, Sm-153,
Lu-177 and Re-188) for therapy. Most efforts are concen-
trated on therapeutic potential for SSTR-positive neuroen-
docrine tumors. Y-90 SMT 487 and Re-188 P2045 have
been studied to show antitumor effect following Ad-medi-
ated delivery of SSTR2 (39).
Iodide uptake in the NIS-transfected tumors was much
higher than that in nontransfected tumors such as anaplas-
tic thyroid cancer, corresponding to NIS mRNA expression
in tumors, and can be selectively killed by the I-131 sodi-
um iodide. Combining the targeting and expression of NIS
gene together with radioiodine treatment can be also used
to treat non-thyroid cancers such as hepatoma, melanoma,
colon and ovarian adenocarcinomas (33). NIS gene trans-
fer using tissue-specific promoters provides a way of selec-
tively targeting NIS gene to malignant cells, thereby maxi-
mizing tissue-specific cytotoxicity and minimizing toxic
side effects on nonmalignant cells.
Conclusion
Molecular imaging helps visualize the cellular and/or
molecular process in living tissues. Recent advances in
imaging technologies and gene transfer strategies optimize
gene therapy trials. The development of molecular imaging
probes is most important, and reporter genes are very use-
ful to monitor the delivery, magnitude and time variation
of therapeutic gene transfer. One of the goals in molecular
imaging research is the development of universal imaging
genes. Such generic reporters could then be used to facili-
tate direct imaging of promoter activity over time.
Molecular imaging technologies must have the capability of
non-invasively detecting, measuring, and reporting the ex-
pression of multiple meaningful genes simultaneously. We
are just scratching the surface of complex biochemical
pathways ongoing in biological systems. Micro-PET,
SPECT, MRI and CT, as well as optical and biolumines-
cence cameras are helpful instruments to generate the re-
sults of successful innovation and feasibility studies in ani-
mals.
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